Hypertrophic Cardiomyopathy Pipeline Insight

DelveInsight’s, “Hypertrophic Cardiomyopathy - Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Hypertrophic Cardiomyopathy Understanding

Hypertrophic Cardiomyopathy: Overview

Hypertrophic cardiomyopathy (HCM) is a complex type of heart disease that affects the heart muscle. It causes thickening of the heart muscle (especially the ventricles, or lower heart chambers), left ventricular stiffness, mitral valve changes and cellular changes. HCM also may cause thickening in other parts of the heart muscle, such as the bottom of the heart called the apex, right ventricle, or throughout the entire left ventricle. Hypertrophic cardiomyopathy affects an estimated 600,000 to 1.5 million Americans, or one in 500 people. HCM can be inherited, caused by an abnormality in a gene that codes the characteristics for the heart muscle. There are many genes that can cause HCM. When a gene defect is present, the type of HCM that develops varies greatly within the family. In addition, some people who have the HCM gene may never develop the disease. Hypertrophy may be acquired as a result of high blood pressure or aging. Many people with HCM live a normal life and do not experience health-related problems. Other people with HCM may develop heart conditions that shorten life or decrease the person’s quality of life. Most people with HCM have a low risk for sudden cardiac death. However, HCM is the most common cause of sudden cardiac death in people under age 30. HCM may be best known for its role in cardiac arrest and subsequent death in some young professional athletes. Hypertrophic Cardiomyopathy (HCM) is a medical condition that may be passed on from generation to generation. The type of HCM treatment prescribed depends on: Whether there is narrowing in the outflow tract (the path blood travels to leave the heart), how the heart is functioning, the patient’s symptoms, the age and activity level of the patient, the presence of arrhythmias. Treatment is aimed at minimizing or preventing symptoms and reducing the risk of complications, such as heart failure and sudden cardiac death. Treatment includes risk identification and regular follow-up, lifestyle changes, medications and procedures, as needed.


"Hypertrophic Cardiomyopathy- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertrophic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Hypertrophic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Hypertrophic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertrophic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypertrophic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hypertrophic Cardiomyopathy. 

Hypertrophic Cardiomyopathy Emerging Drugs Chapters

This segment of the Hypertrophic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Hypertrophic Cardiomyopathy Emerging Drugs


Mavacamten: MyoKardia

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin in development for the treatment of patients with symptomatic obstructive Hypertrophic Cardiomyopathy (oHCM). In March, 2021, The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for mavacamten, a novel therapy for symptomatic obstructive Hypertrophic Cardiomyopathy (oHCM). Mavacamten is thought to work by reducing cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance. In clinical and preclinical studies, mavacamten has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance.


IMB-1018972: Imbria pharmaceticals

IMB-1018972 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. It is currently in Phase II stage of development for Hypertrophic Cardiomyopathy and is being developed by Imbria pharmaceticals.


CK274: Cytokinetics

Aficamten (formerly CK-3773274, or CK-274) is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). Aficamten was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Aficamten was designed to reduce the hypercontractility associated with HCM. HCM causes the heart to thicken and stiffen, eventually limiting its ability to pump blood. This happens when myosin, a protein in the muscle responsible for converting chemical energy into the mechanical force that causes muscle contraction, is working too hard to grab or pull on actin, another protein within the sarcomere, resulting in hypercontractility, or too many hands pulling on the rope. Aficamten addresses this hypercontractility by blocking some myosins from
pulling,resulting in less contraction, or fewer hands on the rope. In preclinical models, aficamten reversed and reduced thickening and stiffening of the heart.

Further product details are provided in the report……..

Hypertrophic Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Hypertrophic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Hypertrophic Cardiomyopathy

There are approx. 12+ key companies which are developing the therapies for Hypertrophic Cardiomyopathy. The companies which have their Hypertrophic Cardiomyopathy drug candidates in the most advanced stage, i.e. Pre-registration include, MyoKardia.



DelveInsight’s report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

Hypertrophic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal


Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule


Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertrophic Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypertrophic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertrophic Cardiomyopathy drugs.

Hypertrophic Cardiomyopathy Report Insights

  • Hypertrophic Cardiomyopathy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hypertrophic Cardiomyopathy Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Hypertrophic Cardiomyopathy drugs?
  • How many Hypertrophic Cardiomyopathy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Hypertrophic Cardiomyopathy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertrophic Cardiomyopathy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypertrophic Cardiomyopathy and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Hypertrophic Cardiomyopathy: Overview

  • Causes
  • Mechanism of Action 
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

Hypertrophic Cardiomyopathy– DelveInsight’s Analytical Perspective

Late Stage Products (Pre-Registration)

  • Comparative Analysis

 Mavacamten: MyoKardia

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Last Stage Products (Phase III)

  • Comparative Analysis

CK274: Cytokinetics

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II) 

  • Comparative Analysis

IMB-1018972: Imbria pharmaceticals

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products 

  • Comparative Analysis

Drug name: Company Name

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Hypertrophic Cardiomyopathy Key Companies

Hypertrophic Cardiomyopathy Key Products

Hypertrophic Cardiomyopathy- Unmet Needs

Hypertrophic Cardiomyopathy- Market Drivers and Barriers

Hypertrophic Cardiomyopathy- Future Perspectives and Conclusion

Hypertrophic Cardiomyopathy Analyst Views

Hypertrophic Cardiomyopathy Key Companies


List of Table

Table 1: Total Products for Hypertrophic Cardiomyopathy

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Hypertrophic Cardiomyopathy

Figure 2: Late Stage Products                              

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Novartis
•  Imbria Pharmaceuticals
• Cytokinetics
•  MyoKardia


Forward to Friend

Need A Quote